» Articles » PMID: 39329701

The Oncoprotein Fra-2 Drives the Activation of Human Endogenous Retrovirus Env Expression in Adult T-Cell Leukemia/Lymphoma (ATLL) Patients

Abstract

Human endogenous retroviruses (HERVs) are retroviral sequences integrated into 8% of the human genome resulting from ancient exogenous retroviral infections. Unlike endogenous retroviruses of other mammalian species, HERVs are mostly replication and retro-transposition defective, and their transcription is strictly regulated by epigenetic mechanisms in normal cells. A significant addition to the growing body of research reveals that HERVs' aberrant activation is often associated with offsetting diseases like autoimmunity, neurodegenerative diseases, cancers, and chemoresistance. Adult T-cell leukemia/lymphoma (ATLL) is a very aggressive and chemoresistant leukemia caused by the human T-cell leukemia virus type 1 (HTLV-1). The prognosis of ATLL remains poor despite several new agents being approved in the last few years. In the present study, we compare the expression of HERV genes in CD8-depleted PBMCs from HTLV-1 asymptomatic carriers and patients with acute ATLL. Herein, we show that HERVs are highly upregulated in acute ATLL. Our results further demonstrate that the oncoprotein Fra-2 binds the LTR region and activates the transcription of several HERV families, including HERV-H and HERV-K families. This raises the exciting possibility that upregulated HERV expression could be a key factor in ATLL development and the observed chemoresistance, potentially leading to new therapeutic strategies and significantly impacting the field of oncology and virology.

References
1.
Ishitsuka K . Diagnosis and management of adult T-cell leukemia/lymphoma. Semin Hematol. 2021; 58(2):114-122. DOI: 10.1053/j.seminhematol.2021.02.005. View

2.
Perzova R, Graziano E, Sanghi S, Welch C, Benz P, Abbott L . Increased seroreactivity to human T cell lymphoma/leukemia virus-related endogenous sequence-1 Gag peptides in patients with human T cell lymphoma/leukemia virus myelopathy. AIDS Res Hum Retroviruses. 2014; 31(2):242-9. DOI: 10.1089/AID.2014.0171. View

3.
Gessain A, Barin F, Vernant J, Gout O, Maurs L, Calender A . Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 1985; 2(8452):407-10. DOI: 10.1016/s0140-6736(85)92734-5. View

4.
Taylor G, Matsuoka M . Natural history of adult T-cell leukemia/lymphoma and approaches to therapy. Oncogene. 2005; 24(39):6047-57. DOI: 10.1038/sj.onc.1208979. View

5.
Curty G, Marston J, de Mulder Rougvie M, Leal F, Nixon D, Soares M . Human Endogenous Retrovirus K in Cancer: A Potential Biomarker and Immunotherapeutic Target. Viruses. 2020; 12(7). PMC: 7412025. DOI: 10.3390/v12070726. View